Comparative Pharmacology
Head-to-head clinical analysis: ORPHENADRINE CITRATE versus STRIFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORPHENADRINE CITRATE versus STRIFON FORTE DSC.
ORPHENADRINE CITRATE vs STRIFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties. Its exact mechanism of action is not fully understood, but it is believed to exert its effects by blocking muscarinic acetylcholine receptors and possibly by acting as an NMDA receptor antagonist. It may also have local anesthetic and antihistaminic properties.
Caffeine is a central nervous system stimulant that acts as an antagonist at adenosine receptors (A1 and A2A subtypes), thereby reducing the inhibitory effects of adenosine. Dihydroergotamine is an ergot alkaloid with partial agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. Thioridazine is a typical antipsychotic with high affinity for dopamine D2 receptors and moderate affinity for serotonin 5-HT2A, alpha1-adrenergic, and histamine H1 receptors.
100 mg orally twice daily. Maximum: 250 mg/day.
Chlorzoxazone 500 mg to 750 mg orally three to four times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 14 hours (range 11–20 hours) in adults; may be prolonged in elderly or hepatic impairment.
10-12 hours in healthy adults; prolonged to 18-24 hours in hepatic impairment or elderly
Primarily renal excretion of metabolites; less than 10% excreted unchanged. Also undergoes biliary excretion with fecal elimination of conjugates.
Renal excretion of unchanged drug (70-90%) and glucuronide conjugates; biliary/fecal elimination accounts for <10%
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant